公开(公告)号：US20240360211A1

公开(公告)日：2024-10-31

申请号：US18436088

申请日：2024-02-08

Applicant: Singapore Health Services PTE LTD. ,  National University of Singapore

Inventor： Stuart Alexander Cook ,  Sebastian Schaefer

IPC: C07K16/24 ,  A61K39/00 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/113

CPC classification number: C07K16/244 ,  C07K14/5428 ,  C07K14/7155 ,  C07K16/2866 ,  C12N15/1136 ,  C12N15/1138 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/32 ,  C07K2319/43 ,  C12N2310/14

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

公开(公告)号：US12129301B2

公开(公告)日：2024-10-29

申请号：US17932450

申请日：2022-09-15

Applicant: National University Corporation Tokai National Higher Education and Research System

Inventor： Mitsuro Kanda

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/04 ,  C12N15/113 ,  G01N33/574

CPC classification number: C07K16/286 ,  A61P35/04 ,  C12N15/1138 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57438 ,  G01N33/57446 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/76 ,  C12N2310/141

Abstract: From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.

公开(公告)号：US20240352120A1

公开(公告)日：2024-10-24

申请号：US18442934

申请日：2024-02-15

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Lieping Chen ,  Scott E. Strome ,  Eugene D. Kwon, IV

IPC: C07K16/28 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  C07K16/30 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/569 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/2086 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  C07K16/2827 ,  C07K16/30 ,  C12N15/113 ,  C12N15/1138 ,  C12Q1/6886 ,  G01N33/5088 ,  G01N33/5091 ,  G01N33/56972 ,  G01N33/57407 ,  G01N33/57438 ,  G01N33/57484 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.

公开(公告)号：US20240325506A1

公开(公告)日：2024-10-03

申请号：US18573086

申请日：2022-06-23

Applicant: AvroBio, Inc.

Inventor： Mark DEANDRADE ,  Chris MASON ,  Chris MASON

IPC: A61K38/47 ,  A61K38/17 ,  A61K48/00 ,  A61P3/00 ,  C12N15/113

CPC classification number: A61K38/47 ,  A61K38/1774 ,  A61K48/0033 ,  A61K48/005 ,  A61P3/00 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531

Abstract: Described herein are methods for treating a subject having or at risk of developing Gaucher disease, by administering one or more agents that increase expression and/or activity of glucocerebrosidase (GBA) and/or scavenger receptor class B member 2 (SCARB2), such as pluripotent cells that express GBA and/or SCARB2, and to the subject. Also disclosed are compositions comprising one or more agents that increase the expression and/or activity of GBA and/or SCARB2.

公开(公告)号：US20240309387A1

公开(公告)日：2024-09-19

申请号：US18376217

申请日：2023-10-03

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： James Butler ,  Brian Bettencourt ,  Kallanthottathil G. Rajeev ,  Martin A. Maier ,  Klaus Charisse

IPC: C12N15/113 ,  C12N9/64

CPC classification number: C12N15/1138 ,  C12N9/6424 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/316 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/343 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3533 ,  C12N2320/30

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis.

公开(公告)号：US20240301424A1

公开(公告)日：2024-09-12

申请号：US18657145

申请日：2024-05-07

Applicant: Toolgen Incorporated

Inventor： Seok Joong Kim ,  Yoon-Young Kim ,  Ho-Sung Yu ,  In-Young Jung ,  Jung Min Lee

IPC: C12N15/113 ,  A61K35/14 ,  C07K14/705 ,  C12N5/0783 ,  C12N5/0784 ,  C12N9/22 ,  C12N15/10 ,  C12N15/52 ,  C12N15/63 ,  C12N15/85

CPC classification number: C12N15/1132 ,  A61K35/14 ,  C07K14/70503 ,  C07K14/70564 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C12N5/0637 ,  C12N5/0638 ,  C12N5/064 ,  C12N5/0646 ,  C12N15/102 ,  C12N15/1138 ,  C12N15/52 ,  C12N15/63 ,  C12N15/85 ,  C12N9/22 ,  C12N2310/20 ,  C12N2320/30 ,  Y02A50/30

Abstract: The present invention relates to an artificially manipulated immune system having an improved immune effect. More particularly, the present invention relates to an immune system having functions artificially altered which comprises artificially manipulated immunoregulatory elements and cells containing the same. Contemplated according to a particular embodiment is an immune system comprising artificially manipulated immunoregulatory genes such as PD-1, CTLA-4, A20, DGKα, DGKζ, FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2, and/or expression products thereof

公开(公告)号：US12071626B2

公开(公告)日：2024-08-27

申请号：US17464474

申请日：2021-09-01

Applicant: Duke University

Inventor： Jennifer Freedman ,  Brendon Patierno ,  Bonnie LaCroix ,  Timothy Robinson ,  Bruce Sullenger ,  Daniel George ,  Steven Patierno

IPC: C12N15/11 ,  A61K31/7105 ,  A61K31/7125 ,  A61K45/06 ,  A61P35/00 ,  C07H21/04 ,  C12N15/113 ,  A61K48/00

CPC classification number: C12N15/1138 ,  A61K31/7105 ,  A61K31/7125 ,  A61K45/06 ,  A61P35/00 ,  C07H21/04 ,  C12N15/11 ,  C12N15/1136 ,  A61K48/0066 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2320/31 ,  C12N2320/33 ,  C12N2310/321 ,  C12N2310/3521

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

公开(公告)号：US12060561B2

公开(公告)日：2024-08-13

申请号：US16636622

申请日：2018-08-01

Applicant: CEVEC Pharmaceuticals GmbH

Inventor： Nicole Faust ,  Silke Wissing ,  Nikola Strempel

IPC: C07K14/705 ,  C07K14/71 ,  C07K19/00 ,  C12N5/07 ,  C12N5/071 ,  C12N5/10 ,  C12N5/16 ,  C12N15/09 ,  C12N15/113 ,  C12N15/62 ,  C12N15/63 ,  C12N15/85

CPC classification number: C12N15/62 ,  C07K14/70517 ,  C07K14/71 ,  C07K19/00 ,  C12N5/06 ,  C12N5/0625 ,  C12N5/10 ,  C12N5/16 ,  C12N15/09 ,  C12N15/1138 ,  C12N15/63 ,  C12N15/85 ,  C07K2319/00 ,  C12N2501/105

Abstract: The present invention relates to methods for the selection of a stable producer cell line expressing one or more protein(s) of interest (POIs), comprising the stable transfection of cells with a gene encoding a constitutively active variant of a growth factor receptor, respective methods for the expression of one or more POIs in such stable producer cell lines, and uses of a constitutively active variant of a growth factor receptor as selection marker in the cultivation of cells.

公开(公告)号：US20240262916A1

公开(公告)日：2024-08-08

申请号：US18561127

申请日：2022-05-16

Applicant: METANOIA BIO INC.

Inventor： Slavica TUDZAROVA-TRAJKOVSKA ,  Oppel GREEFF ,  Abraham VAN WYK

IPC: C07K16/28 ,  A61K31/196 ,  A61K31/198 ,  A61K31/245 ,  A61K31/26 ,  A61K31/352 ,  A61K31/357 ,  A61K31/37 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/519 ,  A61K31/661 ,  A61K38/06 ,  A61K38/08 ,  C12N15/113

CPC classification number: C07K16/2857 ,  A61K31/196 ,  A61K31/198 ,  A61K31/245 ,  A61K31/26 ,  A61K31/352 ,  A61K31/357 ,  A61K31/37 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/519 ,  A61K31/661 ,  A61K38/06 ,  A61K38/08 ,  C12N15/1138 ,  C07K2317/569 ,  C12N2310/11

Abstract: The disclosure provides methods and compositions for treating cardiovascular disease with HIF1-a Pathway Inhibitors and PFKFB3 Inhibitors. Exemplary cardiovascular diseases ns treated using the provided methods and compositions include acute coronary syndrome, coronary artery disease, myocardial infarction, coronary heart disease, carditis or cardiomyopathy, an ischemic cardiovascular disease, heart failure, stroke, peripheral vascular disease peripheral arterial disease, and ischemia/reperfusion injury.

公开(公告)号：US20240240190A1

公开(公告)日：2024-07-18

申请号：US18562167

申请日：2022-05-20

Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLECHEN RECHTS ,  UNIVERSITAET HEIDELBERG

Inventor： Darjus TSCHAHARGANEH ,  Stephen KRIEG

IPC: C12N15/113 ,  A61P35/00 ,  G01N33/50

CPC classification number: C12N15/1138 ,  A61P35/00 ,  G01N33/5026 ,  C12N2310/14 ,  G01N2500/10

Abstract: The present invention relates to an inhibitor of mitoferrin-2 for use in treating a cancer with reduced activity of mitoferrin-1 in a subject. The present invention also relates to a method for identifying an inhibitor of mitoferrin-2 comprising (a) contacting a (i) host cell with a reduced mitoferrin-1 activity and (ii) a host cell with a non-reduced mitoferrin-1 activity with a candidate inhibitor of mitoferrin-2. (b) determining growth and/or morphology of the host cells of step (a): (c) identifying an inhibitor of mitoferrin-2 if a growth arrest and/or abnormal morphology is/are detected in step (b) in the host cell having the reduced activity of mitoferrin-1 but not in the host cell with the non-reduced activity of mitoferrin-1. The present invention further relates to a method for identifying a subject susceptible to cancer treatment by an inhibitor of mitoferrin-2, comprising (A) determining mitoferrin-1 activity in a sample of said subject, preferably a sample of cancer cells, and (B) identifying a patient susceptible to cancer treatment by an inhibitor of mitoferrin-2 based on determining step (A).